The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region

Chronic coronary syndromes (CCS) and stable angina are a growing clinical burden worldwide. This is of particular concern in the Gulf region given its high prevalence of cardiovascular risk factors, especially diabetes mellitus and smoking. Despite recommendations on the use of first- and second-lin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advances in therapy 2021-02, Vol.38 (2), p.925-948
Hauptverfasser: Cheng, Kevin, Alhumood, Khaldoon, El Shaer, Fayez, De Silva, Ranil
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 948
container_issue 2
container_start_page 925
container_title Advances in therapy
container_volume 38
creator Cheng, Kevin
Alhumood, Khaldoon
El Shaer, Fayez
De Silva, Ranil
description Chronic coronary syndromes (CCS) and stable angina are a growing clinical burden worldwide. This is of particular concern in the Gulf region given its high prevalence of cardiovascular risk factors, especially diabetes mellitus and smoking. Despite recommendations on the use of first- and second-line anti-anginal medication, management challenges remain. Current guidelines for pharmacologic treatment are not determined by the range of pathophysiological mechanisms of ischaemia and consequent angina, which may occur either in isolation or co-exist. In this article, we highlight the need to improve knowledge of the epidemiology of chronic coronary syndromes in the Middle East and Gulf region, and the need for studies of stratified pharmacologic approaches to improve symptomatic angina and quality of life in the large and growing number of patients with coronary artery disease from this region. We discuss the role of nicorandil, currently recommended as a second-line anti-anginal drug in CCS patients, and suggest that this may be a particularly useful add-on therapy for patients in the Gulf region.
doi_str_mv 10.1007/s12325-020-01582-w
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7889547</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2472111962</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-4dfa4436754b7b6462a4212f296801a83b95c0fc53f06df79172426ddf29c1f83</originalsourceid><addsrcrecordid>eNp9kUlLBDEUhIMoOi5_wIP00Utr9qQvggxu4AIuoKeQSSczke5Ek2nFf290VPTiIbxDfa9SvAJgG8E9BKHYzwgTzGqIYQ0Rk7h-XQIjJDmry8PLYAQFRTUm8n4NrOf8CAspmFwFa4QQhpBgI_BwO7PVdexsFV116U1MOrS-q3yo5kW50EFPbW_D_EMfz1IM3lTjWKZOb9XNW2hT7G3-5k-GzlXXdupj2AQrTnfZbn3NDXB3fHQ7Pq3Pr07OxofntaGUz2vaOk0p4YLRiZhwyrGmGGGHGy4h0pJMGmagM4w4yFsnGiQwxbxtC2GQk2QDHCx8n4ZJb1tTsibdqafk-xJRRe3VXyX4mZrGFyWkbBgVxWD3yyDF58Hmuep9NrbrdLBxyApTgRFCDccFxQvUpJhzsu7nGwTVRydq0Ykql1afnajXsrTzO-DPyncJBSALIBcpTG1Sj3FIoRztP9t3Lb2YDw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2472111962</pqid></control><display><type>article</type><title>The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Cheng, Kevin ; Alhumood, Khaldoon ; El Shaer, Fayez ; De Silva, Ranil</creator><creatorcontrib>Cheng, Kevin ; Alhumood, Khaldoon ; El Shaer, Fayez ; De Silva, Ranil</creatorcontrib><description>Chronic coronary syndromes (CCS) and stable angina are a growing clinical burden worldwide. This is of particular concern in the Gulf region given its high prevalence of cardiovascular risk factors, especially diabetes mellitus and smoking. Despite recommendations on the use of first- and second-line anti-anginal medication, management challenges remain. Current guidelines for pharmacologic treatment are not determined by the range of pathophysiological mechanisms of ischaemia and consequent angina, which may occur either in isolation or co-exist. In this article, we highlight the need to improve knowledge of the epidemiology of chronic coronary syndromes in the Middle East and Gulf region, and the need for studies of stratified pharmacologic approaches to improve symptomatic angina and quality of life in the large and growing number of patients with coronary artery disease from this region. We discuss the role of nicorandil, currently recommended as a second-line anti-anginal drug in CCS patients, and suggest that this may be a particularly useful add-on therapy for patients in the Gulf region.</description><identifier>ISSN: 0741-238X</identifier><identifier>EISSN: 1865-8652</identifier><identifier>DOI: 10.1007/s12325-020-01582-w</identifier><identifier>PMID: 33351175</identifier><language>eng</language><publisher>Cheshire: Springer Healthcare</publisher><subject>Angina, Stable - drug therapy ; Cardiology ; Cardiovascular Agents - therapeutic use ; Endocrinology ; Humans ; Internal Medicine ; Medicine ; Medicine &amp; Public Health ; Nicorandil - therapeutic use ; Oncology ; Pharmacology/Toxicology ; Quality of Life ; Review ; Rheumatology ; Syndrome ; Vasodilator Agents - therapeutic use</subject><ispartof>Advances in therapy, 2021-02, Vol.38 (2), p.925-948</ispartof><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-4dfa4436754b7b6462a4212f296801a83b95c0fc53f06df79172426ddf29c1f83</citedby><cites>FETCH-LOGICAL-c446t-4dfa4436754b7b6462a4212f296801a83b95c0fc53f06df79172426ddf29c1f83</cites><orcidid>0000-0002-1031-4017 ; 0000-0003-1107-2117 ; 0000-0003-1262-9474</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12325-020-01582-w$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12325-020-01582-w$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,777,781,882,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33351175$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cheng, Kevin</creatorcontrib><creatorcontrib>Alhumood, Khaldoon</creatorcontrib><creatorcontrib>El Shaer, Fayez</creatorcontrib><creatorcontrib>De Silva, Ranil</creatorcontrib><title>The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region</title><title>Advances in therapy</title><addtitle>Adv Ther</addtitle><addtitle>Adv Ther</addtitle><description>Chronic coronary syndromes (CCS) and stable angina are a growing clinical burden worldwide. This is of particular concern in the Gulf region given its high prevalence of cardiovascular risk factors, especially diabetes mellitus and smoking. Despite recommendations on the use of first- and second-line anti-anginal medication, management challenges remain. Current guidelines for pharmacologic treatment are not determined by the range of pathophysiological mechanisms of ischaemia and consequent angina, which may occur either in isolation or co-exist. In this article, we highlight the need to improve knowledge of the epidemiology of chronic coronary syndromes in the Middle East and Gulf region, and the need for studies of stratified pharmacologic approaches to improve symptomatic angina and quality of life in the large and growing number of patients with coronary artery disease from this region. We discuss the role of nicorandil, currently recommended as a second-line anti-anginal drug in CCS patients, and suggest that this may be a particularly useful add-on therapy for patients in the Gulf region.</description><subject>Angina, Stable - drug therapy</subject><subject>Cardiology</subject><subject>Cardiovascular Agents - therapeutic use</subject><subject>Endocrinology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Nicorandil - therapeutic use</subject><subject>Oncology</subject><subject>Pharmacology/Toxicology</subject><subject>Quality of Life</subject><subject>Review</subject><subject>Rheumatology</subject><subject>Syndrome</subject><subject>Vasodilator Agents - therapeutic use</subject><issn>0741-238X</issn><issn>1865-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kUlLBDEUhIMoOi5_wIP00Utr9qQvggxu4AIuoKeQSSczke5Ek2nFf290VPTiIbxDfa9SvAJgG8E9BKHYzwgTzGqIYQ0Rk7h-XQIjJDmry8PLYAQFRTUm8n4NrOf8CAspmFwFa4QQhpBgI_BwO7PVdexsFV116U1MOrS-q3yo5kW50EFPbW_D_EMfz1IM3lTjWKZOb9XNW2hT7G3-5k-GzlXXdupj2AQrTnfZbn3NDXB3fHQ7Pq3Pr07OxofntaGUz2vaOk0p4YLRiZhwyrGmGGGHGy4h0pJMGmagM4w4yFsnGiQwxbxtC2GQk2QDHCx8n4ZJb1tTsibdqafk-xJRRe3VXyX4mZrGFyWkbBgVxWD3yyDF58Hmuep9NrbrdLBxyApTgRFCDccFxQvUpJhzsu7nGwTVRydq0Ykql1afnajXsrTzO-DPyncJBSALIBcpTG1Sj3FIoRztP9t3Lb2YDw</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Cheng, Kevin</creator><creator>Alhumood, Khaldoon</creator><creator>El Shaer, Fayez</creator><creator>De Silva, Ranil</creator><general>Springer Healthcare</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1031-4017</orcidid><orcidid>https://orcid.org/0000-0003-1107-2117</orcidid><orcidid>https://orcid.org/0000-0003-1262-9474</orcidid></search><sort><creationdate>20210201</creationdate><title>The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region</title><author>Cheng, Kevin ; Alhumood, Khaldoon ; El Shaer, Fayez ; De Silva, Ranil</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-4dfa4436754b7b6462a4212f296801a83b95c0fc53f06df79172426ddf29c1f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Angina, Stable - drug therapy</topic><topic>Cardiology</topic><topic>Cardiovascular Agents - therapeutic use</topic><topic>Endocrinology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Nicorandil - therapeutic use</topic><topic>Oncology</topic><topic>Pharmacology/Toxicology</topic><topic>Quality of Life</topic><topic>Review</topic><topic>Rheumatology</topic><topic>Syndrome</topic><topic>Vasodilator Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cheng, Kevin</creatorcontrib><creatorcontrib>Alhumood, Khaldoon</creatorcontrib><creatorcontrib>El Shaer, Fayez</creatorcontrib><creatorcontrib>De Silva, Ranil</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Advances in therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheng, Kevin</au><au>Alhumood, Khaldoon</au><au>El Shaer, Fayez</au><au>De Silva, Ranil</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region</atitle><jtitle>Advances in therapy</jtitle><stitle>Adv Ther</stitle><addtitle>Adv Ther</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>38</volume><issue>2</issue><spage>925</spage><epage>948</epage><pages>925-948</pages><issn>0741-238X</issn><eissn>1865-8652</eissn><abstract>Chronic coronary syndromes (CCS) and stable angina are a growing clinical burden worldwide. This is of particular concern in the Gulf region given its high prevalence of cardiovascular risk factors, especially diabetes mellitus and smoking. Despite recommendations on the use of first- and second-line anti-anginal medication, management challenges remain. Current guidelines for pharmacologic treatment are not determined by the range of pathophysiological mechanisms of ischaemia and consequent angina, which may occur either in isolation or co-exist. In this article, we highlight the need to improve knowledge of the epidemiology of chronic coronary syndromes in the Middle East and Gulf region, and the need for studies of stratified pharmacologic approaches to improve symptomatic angina and quality of life in the large and growing number of patients with coronary artery disease from this region. We discuss the role of nicorandil, currently recommended as a second-line anti-anginal drug in CCS patients, and suggest that this may be a particularly useful add-on therapy for patients in the Gulf region.</abstract><cop>Cheshire</cop><pub>Springer Healthcare</pub><pmid>33351175</pmid><doi>10.1007/s12325-020-01582-w</doi><tpages>24</tpages><orcidid>https://orcid.org/0000-0002-1031-4017</orcidid><orcidid>https://orcid.org/0000-0003-1107-2117</orcidid><orcidid>https://orcid.org/0000-0003-1262-9474</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0741-238X
ispartof Advances in therapy, 2021-02, Vol.38 (2), p.925-948
issn 0741-238X
1865-8652
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7889547
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Angina, Stable - drug therapy
Cardiology
Cardiovascular Agents - therapeutic use
Endocrinology
Humans
Internal Medicine
Medicine
Medicine & Public Health
Nicorandil - therapeutic use
Oncology
Pharmacology/Toxicology
Quality of Life
Review
Rheumatology
Syndrome
Vasodilator Agents - therapeutic use
title The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T18%3A13%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Role%20of%20Nicorandil%20in%20the%20Management%20of%20Chronic%20Coronary%20Syndromes%20in%20the%20Gulf%20Region&rft.jtitle=Advances%20in%20therapy&rft.au=Cheng,%20Kevin&rft.date=2021-02-01&rft.volume=38&rft.issue=2&rft.spage=925&rft.epage=948&rft.pages=925-948&rft.issn=0741-238X&rft.eissn=1865-8652&rft_id=info:doi/10.1007/s12325-020-01582-w&rft_dat=%3Cproquest_pubme%3E2472111962%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2472111962&rft_id=info:pmid/33351175&rfr_iscdi=true